Biotest AG (BIO2)

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH.